GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
CARLSBAD, Calif., Feb. 21, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
- March 1, 2018, GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in Snowbird, UT. Due to the format of this event, no webcast is available.
- March 14, 2018 at 10:00am ET, GenMark’s management is scheduled to present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. Interested parties can access the live and archived webcast at www.genmarkdx.com, under the investor relations section.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
